Gavocabtagene autoleucel, a mesothelin-targeting T cell receptor fusion construct, was evaluated recently in a phase I/II clinical trial (NCT03907852) in patients with selected refractory solid tumors expressing mesothelin (malignant pleural mesothelioma, ovarian cancer, and cholangiocarcinoma) and has shown clinical activity with an ORR of 20% and a 6-month OS rate of 70%. The gene discussed is MSLN; the disease is ovarian cancer.